MediPharm Labs (TSE:LABS)
TSX:LABS
LABS Stock Chart & Stats
C$0.08
<C$0.01(7.69%)
At close: 4:00 PM EST
C$0.08
<C$0.01(7.69%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.11
Previous CloseN/A
Volume690.59K
Average Volume (3M)466.64K
Market Cap
C$27.35M
Enterprise ValueC$16.74M
Total Cash (Recent Filing)C$10.81M
Total Debt (Recent Filing)C$201.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding420,755,000
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.57
Price to Sales (P/S)0.58
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$50.39M
Bulls Say, Bears Say
Bulls Say
Regulatory & Manufacturing CredentialsBroad pharmaceutical-grade regulatory approvals create durable market access to regulated export and B2B pharma channels. These credentials raise entry barriers, support higher-margin contract manufacturing, and underpin multi-market growth opportunities over the next 2–6 months and beyond.
Very Low Leverage / Strong Liquidity PositionMinimal debt and material cash provide financial flexibility to fund international expansion, absorb short-term cash burn, and invest in EU‑GMP capacity without urgent refinancing. This balance-sheet strength materially reduces solvency risk over the medium term.
International Medical Revenue GrowthRapid, sustained international medical growth diversifies revenue away from a pressured Canadian market. A >50% revenue share from international markets signals structural revenue mix improvement and supports more predictable, higher-margin B2B/pharma opportunities going forward.
Bears Say
Negative Operating & Free Cash FlowPersistent negative OCF and FCF indicate the company is burning cash to fund operations and investments. Over a 2–6 month horizon this necessitates continued external funding, asset sales, or cost cuts, constraining strategic flexibility and raising liquidity risk if trends persist.
Ongoing Net Losses And Negative MarginsDespite margin improvement, negative operating and net margins show the business is not yet self-sustaining. Continued losses erode equity and limit reinvestment capacity, meaning profitability must materialize or the company faces prolonged reliance on external capital.
Veteran Affairs Reimbursement Cut & Canadian Pricing PressureA structural reimbursement reduction and broader Canadian pricing compression directly lower addressable margin and revenue in DTP channels. As Canada is a home market, sustained pricing headwinds can reduce high-margin domestic demand and pressure consolidated profitability.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.11 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$27.35M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is May 18, 2026 which is in 42 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Mar 30, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.002 by C$0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 420,755,000 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
LABS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and strategic trajectory: revenue growth (8% YoY) driven by a 43% increase in international medical, margin improvements (Q4 gross margin 35%), cost reductions, stronger liquidity (cash $10.8M) and clear product and market progress (new market entries and pharma-grade launches). However, notable negatives remain — continued net losses (-$8.3M), Q4 revenue dip vs prior year, ongoing pricing compression in key markets, an upcoming Veterans Affairs reimbursement cut, and an interim CEO transition. Taken together, the positives around international growth, regulatory differentiation, expense discipline and strengthened balance sheet materially outweigh the challenges, although risks and near-term headwinds persist.View all TSE:LABS earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---